Millipore Sigma Vibrant Logo

SCC295 hERG1a/1b Inducible HEK293 Cell Line

The heteromeric hERG1a/1b Inducible HEK293 cell line, in which hERG1b protein expression is tightly controlled by doxycyclin dose and treatment time, was derived from a homomeric hERG 1a expressing HEK293 cell line

View Products on Sigmaaldrich.com
SCC295
≥1X10⁶ cells/vial   
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
—
Demander le prix
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

       

      Contacter le Service Clients

      Aperçu

      Replacement Information
      Description
      Catalogue NumberSCC295
      DescriptionhERG1a/1b Inducible HEK293 Cell Line
      OverviewHERG channel inhibition assays for preclinical cardiac safety screening of new drug compounds use electorphysiological methodology and employ hERG-expressing recombinant cell lines. Despite evidence that the cardiac IKr potassium current is produced by heteromeric hERG1a/1b channels1, 2, 3, drug screening assays have long relied on homomeric hERG1a alone, because of the instability of hERG 1b expression in so-called “stable” recombinant cell lines4. The novel inducible hERG1a/1b heteromeric cell line offers an improved tool for preclinical cardiac toxicity screening, by enabling more accurate predictions of off-target drug effects on cardiac IKr, particularly in computational models relying on accurate IC50 measurements. hERG1a/1b cells also can facilitate the study of heteromeric assembly of the hERG 1a and 1b subunits during biogenesis.5
      Background InformationHERG channel inhibition assays for preclinical cardiac safety screening of new drug compounds use electorphysiological methodology and employ hERG-expressing recombinant cell lines. Despite evidence that the cardiac IKr potassium current is produced by heteromeric hERG1a/1b channels1, 2, 3, drug screening assays have long relied on homomeric hERG1a alone, because of the instability of hERG 1b expression in so-called “stable” recombinant cell lines4. The novel inducible hERG1a/1b heteromeric cell line offers an improved tool for preclinical cardiac toxicity screening, by enabling more accurate predictions of off-target drug effects on cardiac IKr, particularly in computational models relying on accurate IC50 measurements. hERG1a/1b cells also can facilitate the study of heteromeric assembly of the hERG 1a and 1b subunits during biogenesis.5

      Source
      The heteromeric hERG1a/1b Inducible HEK293 cell line, in which hERG1b protein expression is tightly controlled by doxycyclin dose and treatment time, was derived from a homomeric hERG 1a expressing HEK293 cell line.5

      References
      1. J Biol Chem 2004, 279(43): 44690–44694
      2. Circ Res 2008, 103(7): e81–e95
      3. PNAS 2014, 111(50): 18073-18077
      4. Br J Pharmacol 2011, 164(2b): 419-432.
      5. Biophysical J 2018, Volume 114, Issue 3, Suppl 1, 2 (292a) (Poster Abstract)
      References
      Product Information
      Applications
      ApplicationThe heteromeric hERG1a/1b Inducible HEK293 cell line, in which hERG1b protein expression is tightly controlled by doxycyclin dose and treatment time, was derived from a homomeric hERG 1a expressing HEK293 cell line
      Key Applications
      • Cell Culture
      Application NotesThis product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.
      Biological Information
      Cell Line Type
      • Cardiomyocyte Cells
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assurance• Each vial contains ≥ 1X10⁶ viable cells.
      • Cells are tested negative for infectious diseases by a Human Essential CLEAR panel by Charles River Animal Diagnostic Services.
      • Cells are verified to be of human origin and negative for inter-species contamination from mouse, rat, chinese hamster, Golden Syrian hamster, and Non-human Primate (NHP) as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services
      • Cells are negative for mycoplasma contamination.
      Usage Statement
      • This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges Merck to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsThe cells should be stored in liquid nitrogen until use. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting functionality.
      Packaging Information
      Material Size≥1X10⁶ cells/vial
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      SCC295 04065265944564